Form 4 for SNDX Syndax Pharmaceuticals Inc
Accepted 2025-03-06 00:00:00 ET · period of report 2025-03-04 · accession 0000950170-25-034634 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2025-03-06 | 2025-03-04 | SNDX | Metzger Michael A | CEO, Dir | S - Sale+OE | $15.05 | -7,814 | 300.1K | -3% | -$117.6K |
| DT | 2025-03-06 | 2025-03-04 | SNDX | Metzger Michael A | CEO, Dir | M - OptEx | $7.20 | +7,814 | 307.9K | +3% | +$56.3K |
| DT | 2025-03-06 | 2025-03-04 | SNDX | Metzger Michael A | CEO, Dir | M - OptEx | $0.00 | +7,814 | 0 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-04 | S | D | 7,814 | $15.05 | 300,121 | D | — | — | (F2) The sale prices ranged from $15.00 to $15.27 |
| 2 | Common | Common Stock | 2025-03-04 | M | A | 7,814 | $7.20 | 307,935 | D | — | — | |
| 3 | Derivative | Stock options (Right to buy) | 2025-03-04 | M | A | 7,814 | $0.00 | 0 | D | $7.20 · — to 2025-06-01 | 7,814 Common Stock | (F3) This option is fully vested. |